|
|
 |
PRESS RELEASE:
Millions of
Dollars Redirected HepCop
has publicly denounced the National Institutes of Health (NIH) for
spending millions of dollars budgeted for Hepatitis C
(HCV) on other research agendas. |
|
HCV Research
Funding |
| |
Grants |
Project Number |
Name |
Cost |
Project Title |
| |
NCI |
1K25CA127524-01A1 |
SCHOGGINS,
JOHN |
$126,357
|
Biomarker
Discovery for Hepatitis C Progression using Machine Learning
Techniques |
| |
578686 |
5K22CA129241-02 |
KRATTIGER,
ANATOLE |
$154,978
|
Hepatitis
C Virus Replication and Intracellular Membrane Rearrangement |
| |
|
5R01CA085888-09 |
LUO,
GUANGXIANG |
$297,351
|
Malignant
Complications of Chronic HCV |
| |
NCRR |
5P51RR013986-10 |
LAUER,
GEORG |
$1,015
|
HCV
CENTER STUDIES ON INFECTIOUS HCV |
| |
616873 |
5P41RR011823-13 |
RUSSELL,
MARCIA |
$819
|
IDENTIFICATION OF NOVEL HOST FACTORS INTERACTING WITH NS5A
PROTEIN OF HCV |
| |
|
5P41RR011823-13 |
WEINMAN,
STEVEN |
$819
|
IDENTIFICATION OF THE HEPATITIS C VIRUS (HCV) PROTEOME |
| |
|
5P51RR000165-48 |
GRETCH,
DAVID |
$35,600
|
UNDERSTANDING MECHANISMS OF HCV PERSISTENCE |
| |
|
5P51RR000165-48 |
GRETCH,
DAVID |
$35,600
|
MECHANISMS OF HEPATITIS C VIRUS PERSISTENCE |
| |
|
5P51RR000165-48 |
GRETCH,
DAVID |
$35,600
|
HEPATITIS
C VIRUS: DEFINING HOST DETERMINANTS OF INFECTION OUTCOME |
| |
|
5P51RR013986-10 |
MURTHY,
KRISHNA |
$3,743
|
IMMUNOGENETHERAPY OF CHRONIC HCV CARRIER CHIMPANZEES |
| |
|
5P51RR013986-10 |
MURTHY,
KRISHNA |
$14,972
|
DEFINING
THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE |
| |
|
5P41RR002250-23 |
RAISON,
CHARLES |
$16,231
|
NS3
HELICASE |
| |
|
5P51RR013986-10 |
MURTHY,
KRISHNA |
$3,870
|
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE
HCV VACCINE |
| |
|
5P51RR013986-10 |
MURTHY,
KRISHNA |
$1,649
|
RESTORING
HCV-SPECIFIC T CELL FUNCTIONS IN CHRONIC HEPATITIS C |
| |
|
5P51RR013986-10 |
LAUER,
GEORG |
$1,967
|
GBV-B: A
SMALL PRIMATE MODEL FOR HEPATITIS C INFECTION |
| |
|
5P51RR013986-10 |
MURTHY,
KRISHNA |
$14,972
|
HCV
NUCLEIC ACID VACCINE STUDIES IN CHIMPANZEES |
| |
|
5P51RR013986-10 |
TAI,
ANDREW |
$952
|
INTERFERON GAMMA AND CONTROL OF HCV REPLICATION |
| |
|
5P41RR002250-23 |
HOWELL,
CHARLES |
$16,231
|
HEPATITIS
C VIRUS |
| |
|
5P51RR013986-10 |
TAI,
ANDREW |
$3,933
|
HCV
REPLICATION AND IMMUNITY |
| |
|
5P41RR000862-35 |
REDDY,
RAJENDER |
$1,102
|
INVESTIGATIONS OF THE FUNCTION OF NS4B OF HCV |
| |
|
5P41RR000862-35 |
REDDY,
RAJENDER |
$1,102
|
STUDY OF
HCV RNA-PROTEIN INTERACTIONS |
| |
|
5P41RR000862-35 |
REDDY,
RAJENDER |
$1,102
|
NS5A
PHOSPHORYLATION |
| |
|
5P20RR016460-07 |
MATLOCK,
DENNIS |
$30,939
|
UNWINDING&TRANSLOCATION OF DNA BY NS3 HELICASE FROM
HEPATITIS C |
| |
|
5M01RR012248-12 |
HUSSAIN,
HERO |
$507
|
HEPC |
| |
|
5M01RR000073-45 |
SCHACKMAN, BRUCE |
$28,483
|
SERUM
MARKERS OF FIBROSIS IN CHRONIC HEPATITIS C |
| |
|
5M01RR000065-46 |
ROSEN,
HUGO |
$20,100
|
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC
HEPATITIS C |
| |
|
5M01RR000051-47 |
RITOLA,
KIMBERLY |
$198
|
IMMUNE
RESPONSES IN ACUTE HEPATITIS C INFECTION |
| |
|
5M01RR000051-47 |
LAU,
DARYL |
$2,254
|
QUANTITATIVE LIVER FUNCTION IN EARLY FIBROSIS STAGE HCV
INFECTION |
| |
|
5K23RR022206-03 |
RICE,
CHARLES |
$153,792
|
HCV
Kinetics and Determinants of Relapse |
| |
|
2M01RR000046-48 |
WILLIAMS,
JEFFREY |
$76
|
IMPACT OF
HEPATIC STEATOSIS ON HEPATITIS C |
| |
|
2M01RR000043-48 |
LIOTTA,
DENNIS |
$2,405
|
HCV RNA
TESTING IN HALT-C SUSTAINED VIROLOGIC RESPONDERS |
| |
|
5P41RR004050-20 |
BUCK,
MARTINA |
$1,951
|
INFECTION
AND REPLICATION OF NATURALLY OCCURRING HEPATITIS C VIRUS |
| |
|
5U54RR019507-06 |
MAYOR,
ANGEL |
$184,889
|
HCV RISK
REDUCTION INTERVENTION AS SECONDARY CO-MORBIDITY PREVNT |
| |
NHLBI |
5R01HL079381-05 |
FREISE,
CHRIS |
$589,711
|
Neutralizing Antibodies to Hepatitis C |
| |
666989 |
3R01HL076902-06S1 |
BUSCH,
MICHAEL |
$77,278
|
Natural
history of acute and chronic HCV in blood donors |
| |
NIAAA |
5R43AA016712-02 |
CHING,
SAN |
$100,000
|
Novel
Engineered Synthetic Metallodrugs Directed Against HCV |
| |
291548 |
5U19AI040034-14 |
REDDY,
RAJENDER |
$191,548
|
HCV
Infection Systems and Role of Neutralizing Antibodies in
Hepatitis C |
| |
NIAID |
5U19AI066316-04 |
MARION,
TONY |
$222,521
|
HLA
-Dependent Racial Differences in Immune Response in Chronic
Hepatitis C Virus |
| |
|
5U19AI066345-04 |
LEE,
JOSHUA |
$252,359
|
The Role
of CD8+ T-cell Responses In Acute Hepatitis C Virus
Infection |
| |
|
5U19AI066345-04 |
RADZIEWICZ, HENRY |
$167,689
|
Identification of acute Hepatitis C Virus infection in Rio
de Janerio |
| |
|
5U19AI066345-04 |
SZABO,
GYONGYI |
$129,397
|
Dynamics
of CD4 Responses in Acute Hepatitis C Virus Infection |
| |
|
5U19AI066345-04 |
ALLEN,
TODD |
$252,306
|
CD8 T
Cell Seletive Pressure and Hepatitis C Virus Sequence
Evolution |
| |
|
5U19AI066345-04 |
KOVACS,
ANDREA |
$127,822
|
Acute
Hepatitis C Virus Infection in the Prison Population |
| |
|
5U19AI066332-04 |
MASON,
HUGH |
$286,659
|
Plant-Derived Envelope gpE1/E2 Vaccine for HCV |
| |
|
5U19AI066332-04 |
ARNTZEN,
CHARLES |
$272,474
|
Plant-Based Production of Non-Envelope Antigens of HCV |
| |
|
5U19AI066328-04 |
RITOLA,
KIMBERLY |
$143,390
|
Innate
and Regulatory Immune Responses in Acute HCV |
| |
|
5U19AI066328-04 |
HASSAN,
MANAL |
$216,575
|
Suppression of HCV-specific CD4+ T Cell Function by Core
Protein |
| |
|
5K08AI072191-02 |
PURCELL,
ROBERT |
$128,250
|
Mechanisms of T cell dysfunction in Hepatitis C virus
persistence |
| |
|
5R01AI047347-10 |
EDLIN,
BRIAN |
$455,271
|
Regulation of human T-cell immunity to HCV antigens |
| |
|
5U01AI070802-03 |
NICOSIA,
ALFREDO |
$180,033
|
Development of an Adenovirus based HCV Vaccine: preclinical
safety and immunology |
| |
|
5U19AI066313-04 |
REDDY,
RAJENDER |
$110,208
|
Viral, T
Cell, and Cytokine Determinants of Hepatic Stellate Cell
Activation |
| |
|
5U19AI048231-09 |
KATZE,
MICHAEL |
$234,281
|
Molecular
Analysis of HCV-specific T Cell Responses |
| |
|
5U19AI048231-09 |
KIM,
ARTHUR |
$247,325
|
Natural
Killer Cell Receptors and Hepatitis C |
| |
|
5U19AI048231-09 |
TAI,
ANDREW |
$436,583
|
HCV-Specific Cellular Immunity in Acute Hepatitis C |
| |
|
5U19AI040035-13 |
LI, KUI |
$93,054
|
Interferon Signaling and Cellular Permissiveness for
Hepatitis C Virus (HCV) |
| |
|
5U19AI040035-13 |
GHANY,
MARC |
$133,673
|
Innate
Defenses that Control Hepatitis C Virus (HCV) |
| |
|
5U19AI040035-13 |
LAUER,
GEORG |
$102,200
|
Virus-Host Interactions in Hepatitis C Virus (HCV)
Infections |
| |
|
5U19AI066328-04 |
PILLAI,
SATISH |
$243,476
|
HCV-Host
Interaction during Acute Hepatitis C |
| |
|
1R21AI076834-01 |
DIENSTAG,
JULES |
$183,750
|
Cell
Culture System for Hepatitis C Virus Genotype 1a |
| |
|
1F32AI080122-01 |
SMITH,
MICHAEL |
$56,702
|
Whole-genome siRNA screen for host genes supporting
hepatitis C virus replication |
| |
|
1K08AI075031-01A1 |
CHARLES,
EDGAR |
$140,400
|
The
Pathogenesis of Autoimmunity in Hepatitis C Virus Infection |
| |
|
1K08AI079406-01 |
EKSIOGLU,
ERIKA |
$130,599
|
Novel
antviral targets in Hepatitis C virus NS4B protein |
| |
|
1K99AI077800-01 |
EVERSON,
GREGORY |
$90,000
|
Studies
of hepatitis C virus polarized cell entry and host factor
requirements |
| |
|
1R01AI073335-01A2 |
KAZAKOV,
SERGEI |
$287,713
|
RNA-dependent RNA Synthesis by the Hepatitis C Virus |
| |
|
1R01AI073963-01A1 |
BLANTON,
RONALD |
$500,000
|
Host
Genetic Contribution to HCV Outcomes |
| |
|
1R01AI075090-01A2 |
WHITACRE,
DAVID |
$302,000
|
Function
of NS2 in Hepatitis C Virus Assembly and Release |
| |
|
1R01AI075099-01A1 |
REDDY,
RAJENDER |
$420,000
|
Role of
HCV p7 and NS2 in infectious virus production |
| |
|
1R01AI079031-01 |
LEMON,
STANLEY |
$473,750
|
Discovery
of potent human antibodies for prevention of (recurrent) HCV
infection |
| |
|
5F32AI069693-02 |
DELGADO,
AYMIN |
$49,646
|
Novel
role of NS2 in HCV infection |
| |
|
1R21AI076706-01 |
ALTFELD,
MARCUS |
$263,250
|
Impact of
NK Cell Immune Pressures on HCV Evolution and Viral Fitness |
| |
|
5U19AI040035-13 |
RAY,
RANJIT |
$221,341
|
Cellular
Immune Failure in Acute Hepatitis C |
| |
|
1R21AI079352-01 |
DUBENSKY,
THOMAS |
$249,000
|
Eliciting
neutralizing antibodies against the HCV E2 envelope
glycoprotein |
| |
|
1R41AI072859-01A2 |
BLYN,
LAWRENCE |
$290,535
|
HCV
Genotyping and Drug Resistance Testing by ESI/MS |
| |
|
1R56AI079043-01 |
CHISARI,
FRANCIS |
$473,750
|
Innate
Control of Hepatitis C Virus Infection: Antiviral and
Evasion Mechanisms |
| |
|
1Z01AI000970-03 |
EMOND,
JEAN |
$384,800
|
Molecular
Studies of Hepatitis C Virus. |
| |
|
5U54RR019507-06 |
MAYOR,
ANGEL |
$15,062
|
HCV RISK
REDUCTION INTERVENTION AS SECONDARY CO-MORBIDITY PREVNT |
| |
|
2R01AI060389-07 |
GHANY,
MARC |
$383,372
|
The Host
Response to Hepatitis C Virus |
| |
|
2R56AI060563-05A2 |
RAISON,
CHARLES |
$396,583
|
HCV NS3
and NS5A: Biochemical Mechanisms and Biological Functions |
| |
|
5U19AI066313-04 |
RUSSELL,
MARCIA |
$160,781
|
Hepatitis
C Virus- Induced Steatosis |
| |
|
3U19AI066345-03S1 |
LEE,
JOSHUA |
$12,261
|
Supplemental Funds to Acquire HCV Volunteers |
| |
|
1R21AI065535-01A2 |
RANGSIN,
RAM |
$183,135
|
Developing an in vitro system for HCV propagation |
| |
|
5U19AI066316-04 |
PERLMAN,
DAVID |
$227,085
|
Interferon System Underlie Differential Response to Therapy
for Hepatitis C Virus |
| |
|
5R01AI069000-03 |
RAY,
RANJIT |
$295,433
|
Roles for
microRNA-122 in hepatitis C virus RNA amplification |
| |
|
5R01AI069142-02 |
SHIFFMAN,
MITCHELL |
$333,295
|
Immune
Mechanisms of HCV Persistence and Pathogenesis |
| |
|
5R01AI069285-02 |
LIANG, T.
JAKE |
$126,887
|
Role of
TLR3 Signaling in Control of HCV |
| |
|
5R01AI069952-03 |
BACCHETTI, PETER |
$178,477
|
Statistical methods for modeling hepatitis C fibrosis
progression |
| |
|
5R01AI070101-03 |
GRETCH,
DAVID |
$401,835
|
Mechanisms of hepatitis C virus persistence |
| |
|
5R01AI070827-03 |
SU,
LISHAN |
$231,928
|
High
Throughput in vitro Hepatitis C Virus Screening |
| |
|
5R01AI068966-03 |
KAY, MARK |
$233,034
|
Cellular
Immune Responses in Subjects Exposed to Hepatitis C |
| |
|
5U01AI070834-04 |
ECKELS,
DAVID |
$354,663
|
Development of Listeria-Based Clinical Consensus HCV Vaccine
Candidates |
| |
|
5R01AI072613-02 |
REDDY,
RAJENDER |
$414,473
|
Identification and characterization of cellular factors
involved in HCV entry |
| |
|
5R03AI067440-03 |
MOHAMED,
MOSTAFA |
$43,078
|
Feasibility for non-Invasive screening for HCV related
fibrosis |
| |
|
5R03AI069090-02 |
OPELLA,
STANLEY |
$95,648
|
Role of
mitochondrial core protein in Hepatitis C Virus pathogenesis |
| |
|
5R21AI070769-02 |
LUO,
GUANGXIANG |
$215,575
|
Hepatitis
C virus infection and lipoproteins |
| |
|
5R21AI072180-02 |
DASH,
SRIKANTA |
$188,843
|
Towards
Developing type 1a HCV cell culture model |
| |
|
5R37AI047367-09 |
TAI,
ANDREW |
$541,702
|
HCV-specific T cell response |
| |
|
5R43AI072780-02 |
O'BRIEN,
THOMAS |
$287,309
|
Broadly
Neutralizing MAbs against Hepatitis C Virus |
| |
|
5R43AI072785-02 |
TIEN,
PHYLLIS |
$300,000
|
Development of a Proplylactic HCV Vaccine |
| |
|
5R01AI072012-02 |
HINKIN,
CHARLES |
$367,061
|
New
Antiviral Therapies for Hepatitis C Infection |
| |
|
5R01AI047365-09 |
RAY,
RANJIT |
$362,764
|
Structure
and Function of the Hepatitis C Virus Genome |
| |
|
5R01AI047519-10 |
CHANG,
KYONG-MI |
$304,162
|
Cellular
immunity - outcome hepatitis C virus infection |
| |
|
1F32AI080093-01 |
POLYAK,
STEPHEN |
$44,846
|
Reconstitution of Poliovirus and HCV RNA Replication
Complexes on Membranes |
| |
|
7R01AI069285-03 |
LIANG, T.
JAKE |
$128,837
|
Role of
TLR3 Signaling in Control of HCV |
| |
|
5R01AI057591-04 |
HASSAN,
MANAL |
$282,356
|
Alteration of innate immunity by HCV core |
| |
|
5R01AI049574-08 |
LAUER,
GEORG |
$311,605
|
GBV-B: A
Small Primate Model for Hepatitis C Infection |
| |
|
5R01AI068769-03 |
RANGSIN,
RAM |
$315,056
|
QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT
VACCINE IN HUMANS |
| |
|
5R01AI050798-05 |
MCKEATING,
JANE |
$200,490
|
Functional analysis of hepatitis C virus glycoproteins |
| |
|
5R01AI061158-04 |
NELSON,
DAVID |
$304,514
|
Mechanisms of Innate and Adaptive Immunity In HCV |
| |
|
5R01AI061684-05 |
BHARDWAJ,
NINA |
$571,176
|
Dendritic
Cell mediated induction of Anti-HCV immunity |
| |
|
5U19AI040034-14 |
REDDY,
RAJENDER |
$26,423
|
HCV
Infection Systems and Role of Neutralizing Antibodies in
Hepatitis C |
| |
|
5R01AI065985-03 |
BLIGHT,
KERIL |
$289,575
|
Defining
NS4B Function in Hepatitis C Virus Replication |
| |
|
5R01AI066209-03 |
HARRISON-FINDIK,
DUYGU DEE |
$408,680
|
Viral
Host Interactions in Hepatitis C |
| |
|
5R01AI067926-03 |
ALLEN,
TODD |
$169,784
|
CD8 T
Cell Selective Pressure and HCV Sequence Evolution |
| |
NIDA |
5R01DA024565-02 |
RAY,
RANJIT |
$503,137
|
Mechanisms of Hepatitis C Virus Evolution |
| |
|
5R01DA013324-10 |
STERLING,
RICHARD |
$643,505
|
Hepatitis
C Pathogenesis & The Human Genome |
| |
|
5U19AI040035-13 |
RAY,
RANJIT |
$65,513
|
Cellular
Immune Failure in Acute Hepatitis C |
| |
|
5K01DA018268-06 |
BIRK,
ALEXANDER |
$111,000
|
SELECTIVE
INHIBITION OF HCV TRANSLATION BY TETRAPEPTIDE |
| |
|
5U19AI040035-13 |
LI, KUI |
$189,867
|
Interferon Signaling and Cellular Permissiveness for
Hepatitis C Virus (HCV) |
| |
|
1K23DA023467-01A1 |
MORASCO,
BENJAMIN |
$165,533
|
Chronic
Pain and Substance Use in Patients with Hepatitis C |
| |
|
5U19AI040035-13 |
LAUER,
GEORG |
$195,546
|
Virus-Host Interactions in Hepatitis C Virus (HCV)
Infections |
| |
|
5U19AI040035-13 |
GHANY,
MARC |
$108,479
|
Innate
Defenses that Control Hepatitis C Virus (HCV) |
| |
NIDDK |
5R01DK078857-02 |
DE LA
FUENTE, CYNTHIA |
$279,351
|
Interferon modulation of cellular microRNAs in the Hepatitis
C antiviral defense |
| |
|
1R01DK080711-01 |
FAUCI,
ANTHONY |
$294,000
|
Hepatitis
C Virus Quasispecies in the Resistance to Antiviral Therapy |
| |
|
1R01DK077704-01A2 |
RUSSELL,
MARCIA |
$328,313
|
Viral
Hepatitis C and Lipid Homeostasis |
| |
|
1R01DK074673-01A2 |
KINLOCK,
TIMOTHY |
$457,981
|
Impact of
Hepatitis C on Insulin Sensitivity and Insulin Secretion in
Latinos |
| |
|
1F32DK083237-01A2 |
HERSHEY,
JOHN |
$49,646
|
Molecular
mechanism of cellular activation of the hepatitis C virus
polymerase |
| |
|
5R21DK079293-02 |
LUO,
GUANGXIANG |
$179,463
|
Transgenic mouse models of hepatitis C virus replication |
| |
|
1K01DK081736-01 |
TROTTER,
JAMES |
$157,946
|
Genetic
Epidemiology of HCV-related Liver Disease |
| |
|
5R01DK074515-02 |
SNYDER,
NED |
$318,528
|
Role of
HCV Sequence Variation in Pathology |
| |
|
5R21DK074891-02 |
WALKER,
CHRISTOPHER |
$145,040
|
Novel
model of HCV infection of humanized liver in immunocompetent
rats |
| |
|
1Z01DK054503-12 |
LINAS,
BENJAMIN |
$506,679
|
Molecular
Approaches To Vaccine Development For Hepatitis C |
| |
|
1F32DK083252-01 |
COTTON,
DEBORAH |
$54,842
|
Interactions Between Hepatitis C and Serum Lipid Homeostasis |
| |
|
5R01DK064223-05 |
GRANT,
IGOR |
$261,667
|
HCV NS5A:
Molecular Virology and Antiviral Target |
| |
|
5K24DK066144-05 |
FRIEDMAN,
SAMUEL |
$139,317
|
Mentoring
Junior Faculty: Hepatitis C Clinical Research |
| |
|
5K08DK076598-02 |
JONES,
CHRISTOPHER |
$124,308
|
The
Pathogenesis of Steatosis in Hepatitis C Genotype 3
Infection |
| |
|
5K08DK076565-02 |
BIGGINS,
SCOTT |
$121,770
|
Bias in
Retransplantation Survival Models: Selection Criteria and
Hepatitis C |
| |
|
5K08DK070022-05 |
DHEER,
SURENDRA |
$128,946
|
Insulin
Resistance in Hepatitis C Virus Infection |
| |
|
5F32DK081259-02 |
CALARESE,
DANIEL |
$49,646
|
Structural and Functional Studies of Hepatitic C Core and
NS4B Proteins |
| |
|
5F32DK081193-02 |
KAO,
CHENG |
$52,898
|
Characterization of the HCV p7 Protein |
| |
|
5F32DK079860-02 |
RUMPTZ,
MAUREEN |
$49,646
|
Characterization of the Assembly and Egress Pathway of
Hepatitis C Virus |
| |
|
5R01DK066802-05 |
ALPERS,
CHARLES |
$352,173
|
PATHOPHYSIOLOGY OF CRYOGLOBULINEMIC GLOMERULONEPHRITIS |
| |
|
5R01DK062847-06 |
BEHRENS,
SVEN-ERIK |
$87,788
|
Molecular
Determinants of HCV Replication |
| |
|
5R01DK070877-03 |
PAGE-SHAFER, KIMBERLY |
$186,896
|
Immunoglobulin Allotypes in Hepatitis C Virus Infection |
| |
|
1Z01DK075009-03 |
GONZALEZ-PERALTA, REGINO |
$378,094
|
Natural
History, Therapy and Pathogenesis of Chronic Viral Hepatitis
C |
| |
|
1Z01DK054511-02 |
LINAS,
BENJAMIN |
$466,145
|
The
Genetics of Disease Progression and Treatment Response in
Hepatitis C |
| |
|
5R01DK066754-05 |
HASSAN,
MANAL |
$282,304
|
Impaired
T cell function by HCV core |
| |
|
3R01DK074515-02S1 |
SNYDER,
NED |
$13,452
|
Role of
HCV Sequence Variation in Pathology |
| |
|
1R43DK083104-01 |
MILLAN,
MARIA |
$305,200
|
Towards
the creation of HCV-resistant liver cells for
transplantation |
| |
|
5R01DK066939-05 |
BRANCH,
ANDREA |
$370,132
|
Modulation of HCV Gene Expression |
| |
|
5R01DK068361-03 |
ANTHONY,
DONALD |
$241,111
|
Role of
immature DC in host defense against HCV |
| |
|
5F32DK067781-03 |
BRADRICK,
SHELTON |
$52,048
|
Cis- and
Trans-acting Factors in HCV Gene Expression |
| |
NIGMS |
1R01GM081346-01A1 |
KONAN,
KOUACOU |
$272,880
|
Structural basis of protein synthesis by the hepatitis C
virus IRES RNA |
| |
NIMH |
5U54RR019507-06 |
MAYOR,
ANGEL |
$10,497
|
HCV RISK
REDUCTION INTERVENTION AS SECONDARY CO-MORBIDITY PREVNT |
| |
RMAP |
1R03MH085690-01 |
FRIEDLAND,
GERALD |
$25,000
|
Hepatitis
C VIrus NS3 Helicase Inhibitor Discovery |
| |
|
|
Total |
|
|
|
